Mazor Robotics (NASDAQ:MZOR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The brokerage currently has a $61.00 price objective on the medical instruments supplier’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 13.53% from the company’s current price.

According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “

Several other brokerages have also weighed in on MZOR. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a research report on Tuesday, November 7th. TheStreet upgraded shares of Mazor Robotics from a “d” rating to a “c-” rating in a research note on Wednesday, November 8th. Ladenburg Thalmann Financial Services set a $67.00 price target on shares of Mazor Robotics and gave the company a “buy” rating in a research note on Monday, October 30th. Barclays downgraded shares of Mazor Robotics from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $55.00 to $34.00 in a research note on Thursday, October 19th. Finally, BidaskClub downgraded shares of Mazor Robotics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 2nd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. Mazor Robotics has a consensus rating of “Hold” and a consensus target price of $43.17.

Mazor Robotics (NASDAQ MZOR) opened at $53.73 on Wednesday. Mazor Robotics has a 1 year low of $20.50 and a 1 year high of $65.97.

Several hedge funds have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Mazor Robotics by 3.0% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 238,647 shares of the medical instruments supplier’s stock valued at $11,782,000 after acquiring an additional 6,905 shares in the last quarter. Candriam Luxembourg S.C.A. grew its stake in shares of Mazor Robotics by 1.9% in the third quarter. Candriam Luxembourg S.C.A. now owns 159,052 shares of the medical instruments supplier’s stock valued at $7,852,000 after acquiring an additional 2,983 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Mazor Robotics in the third quarter valued at about $6,371,000. EAM Investors LLC grew its stake in Mazor Robotics by 68.2% during the third quarter. EAM Investors LLC now owns 119,083 shares of the medical instruments supplier’s stock worth $5,879,000 after buying an additional 48,299 shares in the last quarter. Finally, Global X MANAGEMENT CO LLC grew its stake in Mazor Robotics by 5,758.8% during the third quarter. Global X MANAGEMENT CO LLC now owns 115,536 shares of the medical instruments supplier’s stock worth $5,704,000 after buying an additional 113,564 shares in the last quarter. Institutional investors and hedge funds own 26.46% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/mazor-robotics-mzor-upgraded-to-buy-at-zacks-investment-research/1760549.html.

About Mazor Robotics

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with Analyst Ratings Network's FREE daily email newsletter.